Up­dat­ed: FDA ap­proves Mi­rati's KRAS drug in non-small cell lung can­cer

FDA grant­ed ac­cel­er­at­ed ap­proval to Mi­rati’s KRAS drug ada­gra­sib, which will be mar­ket­ed as Kraza­ti. The green light comes two days ahead of the ex­pect­ed de­ci­sion and ce­ments the biotech as the sec­ond in the KRAS field be­hind leader Am­gen, mak­er of the May 2021-ap­proved Lumakras.

The nod is for sec­ond-line treat­ment for adult pa­tients with KRAS G12C-mu­tat­ed lo­cal­ly ad­vanced or metasta­t­ic non-small cell lung can­cer (NSCLC).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER